Previous 10 | Next 10 |
The South Korean regulatory authority has approved Oxford Immunotec's ([[OXFD]] +1.3%) T-Cell Select reagent kit, an immune cell separation reagent used to automate the preparation of the cells required to run the Company’s T-SPOT.TB test, for diagnosis of TB i...
OXFORD, United Kingdom and MARLBOROUGH, Mass., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company today announced that the Company’s T-Cell Select reagent kit has been approved for ...
Oxford Immunotec Global (OXFD) and RIKEN Genesis Co, a subsidiary of The Sysmex Corporation (Sysmex), in Japan come together, where latter will exclusively distribute the T-SPOT Discovery SARS-CoV-2 kit, developed by Oxford Immunotec for the detection and measurement of SARS-Co...
OXFORD, United Kingdom and MARLBOROUGH, Mass., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company today announces it has entered into an exclusive distribution agreement with RIKEN Genesis Co....
OXFORD, United Kingdom and MARLBOROUGH, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today announced that it plans to hold a virtual investor event on Thursday, December 17, 2020. Dr. Peter Wri...
Oxford Immunotec Global PLC ([[OXFD]] +0.8%) announces results from a prospective study in the U.K. that demonstrated the ability of its T-SPOT Discovery SARS-CoV-2 test to detect PCR-confirmed COVID-19 infections that were negative via blood (serology) tests for antibodies.T-SPOT, for resear...
OXFORD, United Kingdom and MARLBOROUGH, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company, today announced the release of data from a prospective cohort study in keyworkers in the UK &...
The following slide deck was published by Oxford Immunotec Global PLC in conjunction with their 2020 Q3 earnings call. For further details see: Oxford Immunotec Global PLC 2020 Q3 - Results - Earnings Call Presentation
If approved, the T-Cell Select reagent kit would enable automated sample preparation and the T-SPOT ® .TB test to be used with blood samples stored for up to 54 hours at room temperature OXFORD, United Kingdom and MARLBOROUGH, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Oxford...
Image source: The Motley Fool. Oxford Immunotec Global PLC (NASDAQ: OXFD) Q3 2020 Earnings Call Nov 3, 2020 , 8:00 a.m. ET Operator Continue reading For further details see: Oxford Immunotec Global PLC (OXFD) Q3 2020 Earnings Call Transcr...
News, Short Squeeze, Breakout and More Instantly...
Oxford Immunotec Global PLC Company Name:
OXFD Stock Symbol:
NASDAQ Market:
Oxford Immunotec Global PLC Website:
Oxford Immunotec Submits Emergency Use Authorization Request to the FDA and CE Marks T-SPOT®.COVID, a Test for the Detection of a Cell Mediated (T cell) Immune Response to SARS-CoV-2 Infection Canada NewsWire OXFORD , United Kingdom and MARLBOROUGH, Ma...
OXFORD, United Kingdom and MARLBOROUGH, Mass., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company today announces it has worked with GC MS and MESDIA Co., Ltd. to enter into an MOU to market t...
OXFORD, United Kingdom and MARLBOROUGH, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company, today announces an update to the configuration of the T-SPOT Discovery SARS-CoV-2 kit. Th...